

Karin Potthoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7667622/publications.pdf>

Version: 2024-02-01

16
papers

679
citations

1307594

7
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

1183
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. <i>Cancer Treatment Reviews</i> , 2017, 52, 91-104.	7.7	398
2	Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1190-1200.	6.3	72
3	Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data. <i>British Journal of Sports Medicine</i> , 2019, 53, 812-812.	6.7	67
4	Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow-up. <i>International Journal of Cancer</i> , 2018, 142, 1148-1157.	5.1	47
5	Factors influencing participation in a randomized controlled resistance exercise intervention study in breast cancer patients during radiotherapy. <i>BMC Cancer</i> , 2015, 15, 186.	2.6	42
6	Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). <i>European Journal of Haematology</i> , 2018, 101, 766-773.	2.2	10
7	Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR. <i>Current Medical Research and Opinion</i> , 2019, 35, 1127-1138.	1.9	9
8	Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials. <i>Leukemia Research</i> , 2018, 68, 90-97.	0.8	6
9	Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study). <i>European Journal of Haematology</i> , 2019, 102, 174-181.	2.2	6
10	Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma (R/RMM): Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. <i>European Journal of Haematology</i> , 2021, , .	2.2	6
11	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (<scp>LICC</scp>, <scp>CELIM</scp>, <scp>FIRE</scp>). <i>International Journal of Cancer</i> , 2022, 150, 1341-1349.	5.1	6
12	Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 6633-6643.	2.2	5
13	Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 286.	2.6	3
14	Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies. <i>Oncology Research and Treatment</i> , 2021, 44, 1-9.	1.2	1
15	Effects of resistance training on fatigue and quality of life in breast cancer patients undergoing radiotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9534-9534.	1.6	1
16	Reversible posterior leucoencephalopathy syndrome (RPLS) associated with pazopanib.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15574-e15574.	1.6	0